(Q43681771)

25 November 2017

Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections (English)

1 reference

25 November 2017

2

File TM

1 reference

25 November 2017

Ball P

1

1 reference

PubMed ID

11463522

25 November 2017

Twynholm M

series ordinal

3

1 reference

PubMed ID

11463522

25 November 2017

Henkel T

series ordinal

4

1 reference

25 November 2017

1 July 2001

1 reference

International Journal of Antimicrobial Agents

25 November 2017

1 reference

25 November 2017

18

1 reference

25 November 2017

1

1 reference

25 November 2017

19-27

1 reference

Community-acquired pneumonia: epidemiology, etiology, treatment

25 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Epidemiology of chronic airways disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Acute exacerbations of chronic bronchitis: an international comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Antimicrobial resistance in respiratory tract pathogens: results of an international surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Haemophilus influenzae and Moraxella catarrhalis from patients with community-acquired respiratory tract infections: antimicrobial susceptibility patterns from the SENTRY antimicrobial Surveillance Program (United States and Canada, 1997)

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

New Fluoroquinolones: Real and Potential Roles

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Prevention of neural-tube defects

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

1 reference

7 January 2021

Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Comparative tolerability of the newer fluoroquinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Comparative in vitro activity of gemifloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Antimicrobial activity and spectrum of LB20304, a novel fluoronaphthyridone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Determinants of non-compliance with short term antibiotic regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

Managing community-acquired pneumonia. Factors to consider in outpatient care

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

New regression equations for predicting peak expiratory flow in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2801%2900359-4

7 January 2021

10.1016/S0924-8579(01)00359-4

Identifiers

DOI

1 reference

25 November 2017

1 reference

PubMed ID

11463522